Cargando…

Muc4\sialomucin Complex, A Specific Intramembrane Modulator of ERBB2/HER2/NEU, Potentiates Primary Tumor Growth and Suppresses Apoptosis in A Xenotransplanted Melanoma

Detalles Bibliográficos
Autores principales:	Carraway, Coralie Carothers, Komatsu, Masanobu, Jepson, Scott, Arango, Maria, Carraway, Kermit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2001
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084049/ https://www.ncbi.nlm.nih.gov/pubmed/30147626 http://dx.doi.org/10.1100/tsw.2001.23.248

Ejemplares similares

A New Monoclonal Antibody Demonstrates That Muc4, the Intramembrane Ligand for Erbb2/Her2/Neu, Is Overexpressed in Multiple Carcinomas
por: Zhang, Jin, et al.
Publicado: (2002)

Effect of interferon-γ (IFN-γ) on transforming growth factor-β (TGF-β) regulation of sialomucin complex/Muc4
por: Price-Schiavi, SA, et al.
Publicado: (2001)

Conformational changes in receptor tyrosine kinase signaling: an ErbB garden of delights
por: Carraway, Kermit L, et al.
Publicado: (2009)

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Negative regulation of ErbB family receptor tyrosine kinases
por: Sweeney, C, et al.
Publicado: (2004)

The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells
por: Workman, Heather C, et al.
Publicado: (2009)

Repurposing Cationic Amphiphilic Drugs and Derivatives to Engage Lysosomal Cell Death in Cancer Treatment
por: Hu, Michelle, et al.
Publicado: (2020)

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Evaluation of C-ErbB-2 Overexpression and Her-2/neu Gene Copy Number Heterogeneity in Barrett’s Adenocarcinoma
por: Walch, Axel, et al.
Publicado: (2000)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014)

Vangl as a Master Scaffold for Wnt/Planar Cell Polarity Signaling in Development and Disease
por: Dreyer, Courtney A., et al.
Publicado: (2022)

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
por: Montañez-Wiscovich, ME, et al.
Publicado: (2009)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

A Cell-Permeant Amiloride Derivative Induces Caspase-Independent, AIF-Mediated Programmed Necrotic Death of Breast Cancer Cells
por: Leon, Leonardo J., et al.
Publicado: (2013)

Clear Cell Basal Cell Carcinoma with Sialomucin Deposition
por: Kim, Do Young, et al.
Publicado: (2006)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Showalter, Megan Reed, et al.
Publicado: (2017)

Activation of the Her2/neu receptor leads to antiestrogen resistance, but acquired resistance is not caused by altered ErbB expression and activation
por: Larsen, SS, et al.
Publicado: (2000)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor
por: Gossel, Leonie D. H., et al.
Publicado: (2021)

The Baboon in Xenotransplant Research
por: Bailey, Leonard L.
Publicado: (2009)

Transgenic Organs and Xenotransplants
por: Costa Vallés, Cristina, et al.
Publicado: (2012)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

Structural basis for the oncogenic signalling complex formed by Grb2 and Gab2 in Her2 (ErbB2/Neu)-driven breast cancers and CML cells
por: Tsirka, T, et al.
Publicado: (2009)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Expression of HER-2/neu in Oral Squamous Cell Carcinoma
por: Mirza, Sana, et al.
Publicado: (2020)

Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines
por: Cui, Hai, et al.
Publicado: (2014)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d8d4957bnmu6b48nh0sktbj226